Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | GCK | P35557 | 6/20 | 0.39 |
| ▸ | NAMPT | P43490 | 4/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | CCR6 | P51684 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13442882 | 0.84 | MMP13 (0.41) | MMP13GCKNAMPTMMP1MMP8 | |
| SCHEMBL22638680 | 0.83 | CA1 (0.54) | CA12CA1CA2CA9CA14 | |
| SCHEMBL184966 | 0.83 | ALDH1A1 (0.44) | MMP13KMT2AMEN1 | |
| SCHEMBL2666628 | 0.82 | GCK (0.43) | MMP13GCKMMP1MMP8MMP2 | |
| SCHEMBL2656535 | 0.80 | CPT1B (0.45) | MMP13GCKKCNH2CCR6CA12 | |
| SCHEMBL19859448 | 0.78 | ENPP2 (0.47) | KMT2A | |
| SCHEMBL10230021 | 0.76 | GCK (0.41) | MMP13GCKMMP1MMP8MMP2 | |
| SCHEMBL13408358 | 0.76 | GCK (0.61) | MMP13GCKMMP2MMP9KCNH2 | |
| SCHEMBL623611 | 0.76 | DDIT3 (0.41) | GCKNAMPT | |
| SCHEMBL2594743 | 0.75 | CA1 (0.53) | KCNH2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119626-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-02-21 | — | — | US | disclosed |
| US-8119626-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20100099662-A1 | HYDRAZONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099662-A1 | HYDRAZONE DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20090291936-A1 | OXIME DERIVATIVE AND PREPARATIONS THEREOF | SUGAWARA KAZUTOSHI | 2009-11-26 | — | — | US | disclosed |
| US-20090291936-A1 | OXIME DERIVATIVE AND PREPARATIONS THEREOF | SUGAWARA KAZUTOSHI | 2009-11-26 | — | — | US | disclosed |
| EP-2105435-A1 | HYDRAZONE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-09-30 | — | — | EP | disclosed |
| US-7514439-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-7514439-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| WO-2007007886-A1 | AN OXIME DERIVATIVE AND PREPARATIONS THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | GCK, KHK, GCKR | MMP13 2769/4885GCK 1/4885NAMPT 1129/4885 |
| US-20090291936-A1 | OXIME DERIVATIVE AND PREPARATIONS THEREOF | GCK, KHK, GCKR | MMP13 2769/4885GCK 1/4885NAMPT 1129/4885 |
| US-20100099662-A1 | HYDRAZONE DERIVATIVE | GCK, GCKR, HK1 | MMP13 1881/4885GCK 1/4885NAMPT 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.